Results for tag: "Heplisav B"

Heplisav B is a vaccine developed by Dynavax Technologies Corporation for the prevention of hepatitis B virus (HBV) infection. It is a recombinant vaccine, meaning it is made from a combination of two different HBV proteins. The vaccine is administered in two doses, one month apart, and is approved for use in adults 18 years of age and older. Heplisav B is the first and only two-dose HBV vaccine approved by the US Food and Drug Administration (FDA). Heplisav B is a part of the larger market of vaccines, which are biological preparations that provide active acquired immunity to a particular disease. Vaccines are used to prevent and treat a wide range of infectious diseases, including influenza, measles, and polio. Vaccines are typically administered through injection, but can also be administered orally or nasally. The Heplisav B market includes companies such as Dynavax Technologies Corporation, Merck & Co., GlaxoSmithKline, Sanofi, and Pfizer. These companies are involved in the research, development, manufacturing, and distribution of Heplisav B and other vaccines. Show Less Read more